This clinical study focuses on Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE), which are autoimmune conditions where the body’s immune system attacks its own tissues. SLE can affect multiple organs throughout the body, while CLE primarily affects the skin, causing rashes and lesions. The study will test a new medication called enpatoran in patients who are already receiving standard treatments for lupus.
The purpose of this research is to evaluate how different doses of enpatoran work in reducing disease activity, particularly focusing on skin symptoms and overall disease control. During the study, participants will receive either enpatoran tablets or placebo in addition to their current lupus medications. The study will track changes in participants’ symptoms and overall health for up to 24 months.
This is a Phase 2 study, which means the medication has already been tested for basic safety in humans, and researchers are now studying how well it works at different doses. The study is designed to be double-blind, which means neither the participants nor the healthcare providers will know who is receiving enpatoran or placebo during the study period.
Bulgaria 
Greece 
Poland 
Romania 
Spain 
